Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis

A Double-Blind, Placebo-controlled Trial

Sarah L. Morgan, MD, RD; Joseph E. Baggott, PhD; William H. Vaughn, BS; Janet S. Austin, MA; Tonya A. Veitch, BS; Jeannette Y. Lee, PhD; William J. Koopman, MD; Carlos L. Krumdieck, MD, PhD; and Graciela S. Alarcón, MD, MPH

■ *Objective:* To determine the effect of two different weekly doses of folic acid on the toxicity and efficacy of low-dose methotrexate therapy for rheumatoid arthritis.

■ *Design:* Randomized, double-blind, placebo-controlled study.

■ *Patients:* 79 persons between 19 and 78 years of age who fulfilled the American Rheumatism Association's criteria for rheumatoid arthritis.

■ *Intervention:* Participants were randomly assigned to visually identical placebo or to 5 mg or 27.5 mg of folic acid each week.

■ *Measurements:* Duration, intensity, and clinical severity of toxic events; efficacy (indices of joint tenderness and swelling and grip strength); plasma and erythrocyte folate levels; and other laboratory variables.

■ *Results:* Folic acid supplementation at either dose did not affect the efficacy of methotrexate therapy as judged by joint indices and patient and physician assessments of disease. Patients given folic acid supplements had lower toxicity scores than did participants given placebo ($P \leq 0.001$). Low blood folate levels and increased mean corpuscular volumes were associated with substantial methotrexate toxicity, whereas daily dietary intakes of more than 900 nmol (400 μg) of folic acid were associated with little methotrexate toxicity.

■ *Conclusions:* Folic acid, an inexpensive vitamin, is safe in a broad range of doses and protects patients with rheumatoid arthritis who are taking methotrexate from toxicity while preserving the efficacy of methotrexate.

The folic acid antagonist methotrexate (N-10-methyl-aminopterin) is useful in low doses (2.5 to 20 mg/wk) for treating chronic inflammatory diseases (1–7). Many trials have established the efficacy of methotrexate in rheumatoid arthritis (7–13). Compared with other disease-modifying drugs, methotrexate has the highest probability of drug continuation at 10 years. Dose response–related toxic effects have been reported in 30% to 90% of patients given methotrexate (13). Toxic effects include gastrointestinal intolerance, hematologic abnormalities, alopecia, hepatotoxicity, and pulmonary toxicity (14–22).

Some side effects of methotrexate administration, such as gastrointestinal intolerance, mimic complicated folate deficiency (23). Folate deficiency occurs frequently in patients with rheumatoid arthritis; further, folate stores are decreased in patients with rheumatoid arthritis who take methotrexate, suggesting that impaired folate status is related to toxicity (24–26).

Folic acid supplementation has been reported anecdotally to lessen toxicity in patients receiving methotrexate treatment (27, 28). In a 6-month, double-blind, placebo-controlled trial, 7 mg of folic acid weekly (1 mg/d or 2265 nmol/d) decreased methotrexate toxicity without affecting efficacy (29). This was confirmed by Stewart and colleagues (30) in a retrospective chart review.

Folinic acid (leucovorin, citrovorum factor) is a one-carbon–substituted, fully reduced folate that has also been administered during methotrexate therapy (31–36). Low doses of the vitamin (1 to 7 mg/wk) have decreased methotrexate toxicity (35, 36). Higher doses negate efficacy and lessen toxicity (31, 32). Thus, the folinic acid dose may critically affect the efficacy of methotrexate therapy.

The influence of the folic acid dose on methotrexate toxicity and efficacy remains controversial, and the effects of different doses of folic acid are not known (37, 38). Some investigators argue that if toxic effects occur, the most rational approach is to reduce the dose of methotrexate rather than to provide folic acid supplements (37). We designed a larger and longer study to evaluate different doses of folic acid, assuming that toxicity could be reduced without changing the efficacy of methotrexate.

Methods

Participants

Patients aged 19 to 78 years who fulfilled the American College of Rheumatology's revised criteria for rheumatoid arthritis

consented to participate in the trial (39). Enrollment criteria included rheumatoid arthritis diagnosed more than 6 months previously, onset after the age of 16 years, and at least three of the following signs or symptoms: 3 or more swollen joints, 6 or more tender joints, at least 45 minutes of morning stiffness, and a Westergren erythrocyte sedimentation rate greater than or equal to 28 mm/h.

Referring rheumatologists and the principal investigator did the screening. Exclusion criteria included serious concomitant medical illnesses, liver enzyme levels twice the upper limit of normal, leukocyte counts less than 3.5×10^9/L or platelet counts less than 150×10^9/L, and use of methotrexate within the past 6 months. Gold salts were stopped for at least 10 days before the trial. This short washout period mirrors actual rheumatology practice. Patients remained under the care of their rheumatologists, abstained from alcohol use, did not become pregnant, and received stable doses of aspirin and nonsteroidal anti-inflammatory drugs. If prednisone was taken at entry, the dose could not exceed 10 mg/d. Hydroxychloroquine therapy was allowed during the study.

Study Design

Figure 1 shows the trial design. To maintain the double-blind status of the trial, the statistician carried out the randomization using a computer program in which the algorithm was transparent and a coded vial number represented the treatment assignment. Patients were assigned to treatment groups by a sequential treatment assignment process designed to balance the sample with respect to baseline features, including age, sex, folate-containing vitamin use, rheumatoid factor status, and prednisone use (40). Patients agreed to discontinue therapy with folate-containing vitamins during the trial. Rheumatoid factor was considered positive if the level was more than 30 IU/mL or if the titer was more than 1:160. Patients received either visually identical placebo or 5 mg (low-dose folic acid group) or 27.5 mg folic acid (high-dose folic acid group) each week, prepared by the Hospital Investigational Drug Service. Spectrophotometric analysis indicated that the mean ± SD folic acid content was 1 ± 0.15 mg ($2.3 \pm 0.3 \mu$mol) and 5.5 ± 0.3 mg ($12.5 \pm 0.7 \mu$mol) per capsule in the low-dose and high-dose folic acid groups, respectively. Lederle Laboratories provided the methotrexate (Rheumatrex; Pearl River, New York), which was started in a median oral dose of 16.5 μmol (7.5 mg) per week and increased in 5.5-μmol (2.5 mg) increments at the rheumatologist's discretion. Methotrexate was taken either in an undivided or a divided dose (that is, every 12 hours for three doses). The methotrexate dosing regimens were identical among the study groups. Folic acid supplements were given 5 days per week when methotrexate was not ingested. Compliance with the regimen was reinforced using a digital reminder cap (Counter Cap; Senetics, Boulder, Colorado). All participants and investigators were blinded to vitamin capsule content until the study was complete.

Clinical Assessment

Patients were evaluated immediately before methotrexate initiation at a mean of 13, 26, 39, and 53 weeks (Figure 1). Each patient was assessed by the same physician–nutritionist (SLM). Two research assistants (JSA or WHV) did the joint evaluations. In most cases, patients were examined by the same observer throughout the study. The joint counts for tenderness and swelling were not significantly different between the two observers ($P = 0.6$ for tenderness; $P = 0.9$ for swelling). The following variables were evaluated at each visit: 1) number of the 58 diarthrodial joints with swelling; 2) number of the 60 joints with tenderness on pressure or with pain on passive motion (or both); 3) joint swelling and tenderness indices, expressed as a sum, with each joint graded for swelling as 0 (none), 1 (mild), 2 (moderate), or 3 (severe); 4) mean grip strength (three measurements) for both hands expressed in mm Hg; 5) duration of morning stiffness expressed in hours; 6) patient's and physician's global assessments of disease activity graded as 0 (asymptomatic), 1 (mild), 2 (moderate), 3 (severe), or 4 (very severe); 7) current medications and doses; 8) a 1-day dietary recall using the Minnesota Nutrition Data System software, Food Database version 6A, Nutrient Database version F21 (41); 9) eight activities of

daily living assessed and averaged at baseline and at 12 months using the modified Health Assessment Questionnaire and scored on a scale of 1 (no difficulty) to 4 (unable to perform) (42); and 10) presence, duration, intensity, and severity of toxic effects at every follow-up visit and every 3 weeks by telephone interview (done by SLM).

Laboratory Assessments

At the initial visit, complete blood cell count, Westergren erythrocyte sedimentation rate, liver enzyme (aspartate amino transferase and alkaline phosphatase), rheumatoid factor by nephelometry, and serum creatinine values were obtained. The complete blood cell count, creatinine, and liver function tests were repeated at all visits. If laboratory values were obtained more frequently than stipulated in the protocol, they were recorded and became part of the toxicity score.

Blood for plasma and erythrocyte folate levels, using a methotrexate-resistant *Lactobacillus casei* microbiological assay, was drawn at all visits (43). At baseline, blood was drawn for a vitamin panel (plasma and erythrocyte folate, vitamins B_{12}, A, C, and E, carotene, riboflavin, thiamin, pyridoxine) (44–51). If patients had abnormal values for any of the vitamins, other than folate, the abnormality was treated with single vitamin supplements.

Radiographic Assessment

Hand and wrist radiographs taken within 6 months of entering the trial were assessed by one of the rheumatologists (GSA) without knowledge of study status. Joint erosions and space narrowing were determined by the modified method of Sharp (52). Results were expressed as the mean raw scores for joint erosion and joint space narrowing.

Toxicity: Frequency and Severity

Toxic effects and discontinuation of therapy with study medications due to toxicity were considered primary outcomes. We determined a toxicity score, modified from the one previously used, for each patient at each visit or until methotrexate therapy was discontinued (29) (Appendix).

Efficacy

We determined patient response to treatment using a modification of the criteria used in our previous folic acid supplementation trial and by others (8, 29, 53). We defined marked improvement in the joint swelling index and the joint tenderness and pain index as a net decrease of 50% or more in value at any


Study Design
Double–Blind

Figure 1. Study design for the double-blind, placebo-controlled trial. The randomization was done by the statistician using a sequential treatment assignment program in which the algorithm was transparent and a coded vial number was used as the treatment assignment.

follow-up visit compared with visit 1. We defined moderate improvement as a 30% to 49% net decrease in the index, and no change as the index value remaining within 30% of the original value. We defined worsening as an increase in the index value of 30% or more.

We examined the effects of folic acid supplementation on changes in physician and patient global assessments, grip strength, morning stiffness, erythrocyte sedimentation rate, findings of the modified Health Assessment Questionnaire, complete blood cell counts, blood folate levels, and dietary folate and vitamin B_{12} intake.

Statistical Analysis

Sample Size and Analysis

In our previous study, the mean toxicity scores for patients receiving low-dose folic acid and placebo recipients were 0.21 and 1.06, respectively, for a difference of 0.85. The sample size tested the null hypothesis for no difference between placebo and low- and high-dose folic acid treatments, with respect to the mean toxicity score. The alternative hypothesis was that the difference in the score between at least one pair of treatments (placebo compared with low-dose folic acid, placebo compared with high-dose folic acid, or low-dose folic acid compared with high-dose folic acid) was greater than or equal to the difference observed previously. As described by Cohen (54) and implemented by Borenstein and Cohen (55), 25 patients per group was a sufficient number to detect a difference in the mean toxicity score of 0.85 between any pair of treatments at a significance level of 0.05 and a power of 0.80.

An underlying assumption in sample size estimates was that the scores are normally distributed. To address the potential non-normal character of the toxicity scores, we increased the sample size estimates by 4% to maintain the significance level and power if nonparametric analyses were used. To allow for a 20% attrition rate, the enrollment goal was 31 patients per group.

Patients were withdrawn if more than 3 weeks of methotrexate treatment was missed for any reason or if noncompliance was documented. Patients who withdrew from the trial because of toxic effects did so after consulting their rheumatologists. Patients contributed to data analyses until therapy with methotrexate was discontinued. For patients who withdrew before receiving 12 months of therapy, we computed toxicity and efficacy data based on data collected until drug therapy was discontinued.

Comparison of Data among Groups

We tested the baseline values of all outcome measures for normality using the Shepin-Wilk statistic. For normally distributed data, we used chi-square analyses to compare proportions and analysis of variance to evaluate the effects of treatment, time, and their interaction.

Non-normal distributions occurred in joint indices for pain and tenderness, physician and patient assessment of disease, grip strength, answers to the modified Health Assessment Questionnaire, and plasma and erythrocyte folate levels. We used the Wilcoxon rank-sum test to compare the three groups and Wilcoxon rank-sum tests for pair-wise comparison, if appropriate.

Comparison of Toxicity Scores

We used the Fisher exact test to compare the incidence of toxic effects in the folic acid and placebo groups. Because the primary outcome measure was the toxicity score, we included data until the study was complete or the participant withdrew. To evaluate the effects of time, treatment group, and their interaction on the toxicity score, we used analysis of variance on the rank of the toxicity scores. We did two-way analyses of variance (or on the ranks for data that were non-normally distributed) to evaluate the effects of time, treatment, and their interaction.

Results

Patients

We enrolled 94 patients (age range, 19 to 78 years) into the trial. Subsequently, we withdrew 15 patients because of noncompliance (numbers were equally distributed among the study groups). Our results are from 79 patients who completed the trial: 25 in the low-dose folic acid group, 26 in the high-dose folic acid group, and 28 in the placebo group. The demographic and selected clinical features of the patients in the three study groups were similar (Table 1). No patients were taking sulfasalazine before enrollment. We found no statistical difference among the groups in previous use of gold salts ($P = 0.92$). Four patients in the placebo group (23%), 4 in the low-dose folic acid group (14.3%), and 6 in the high-dose folic acid group (23%) previously had therapy with methotrexate discontinued because of toxic effects ($P = 0.76$). Patients who previously discontinued methotrexate therapy because of toxic effects were randomly distributed in the three groups. Other initial variables such as hemoglobin level, hematocrit, leukocyte count, mean corpuscular volume, creatinine level, aspartate aminotransferase value,

Table 1. Demographic and Selected Clinical Characteristics of 79 Patients with Rheumatoid Arthritis*

Characteristics	Study Group		
	Placebo (n = 28)	Low-Dose Folic Acid (n = 25)	High-Dose Folic Acid (n = 26)
Mean age, y	52.2 ± 13.0	54.4 ± 14.0	53.2 ± 14.3
Sex, % women	82	76	65
Race, % white	85.7	68	73
Mean disease duration, y	8.5 ± 8.2	7.4 ± 10	11.6 ± 9.5
Previous use of folate-containing vitamins, %	32	28	19
IgM rheumatoid factor positivity (>30 IU/mL or 1:160 titer), %	71	80	85
Concurrent use of aspirin or nonsteroidal anti-inflammatory drugs, %	86	80	88
Concurrent prednisone use, %	79	80	88
Concurrent hydroxychloroquine use, n	1	1	4
Patients previously receiving gold salts, n	16	17	17
Patients previously receiving methotrexate, n	4	6	4
Previous disease-modifying antirheumatic drug use, %	64	68	77
Mean joint erosion score	9.2 ± 9.5	15 ± 16.7	17.7 ± 17.8
Mean joint space narrowing	20.2 ± 20.1	29.1 ± 25.1	35.3 ± 31.1

* All comparisons between groups, $P > 0.05$. Means are expressed ± SD.

Figure 2. Median toxicity scores in the three study groups. The placebo group had a statistically higher toxicity score ($P = 0.001$) than the folic acid supplementation groups. The toxicity score was not significantly different between the low-dose folic acid and high-dose folic acid groups ($P = 0.71$). ▲ = patients withdrawn from the trial because of toxic effects; ○ = patients who completed the trial.

alkaline phosphatase level, and erythrocyte sedimentation rate were also similar among the groups. The erosion and joint space narrowing scores were similar at baseline among the three groups ($P = 0.16$ for joint space narrowing and $P = 0.17$ for erosions; Table 1).

Methotrexate Dose: Folate and B_{12} Intake

We found no statistical differences in mean cumulative methotrexate dose among the three groups. The mean cumulative methotrexate doses at 53 weeks in the placebo, low-dose folic acid, and high-dose folic acid groups were 206 ± 88 mg, 217 ± 113 mg, and 284 ± 187 mg, respectively ($P = 0.24$). The average weekly methotrexate dose was 8.5 ± 1.5 mg, 9.4 ± 2.4 mg, and 9.6 ± 2.6 mg in the placebo, low-dose folic acid, and high-dose folic acid groups, respectively ($P = 0.27$).

The mean dietary folate and vitamin B_{12} intakes among the groups were never statistically different. Median dietary folate intakes were 204 µg/d in the placebo group, 195 µg/d in the low-dose folic acid group, and 230 µg/d in the high-dose folic acid group ($P = 0.37$ for all comparisons). The median daily intakes in all study groups did not substantially differ from the median values of 150 to 250 µg/d reported in the Second National Health and Nutrition Examination series (56).

Primary Outcome: Toxic Effects

Fifty-four patients (68%) experienced some form of toxicity: 25 (89%) in the placebo group, 12 (48%) in the low-dose folic acid group ($P < 0.002$ compared with placebo), and 17 (65%) in the high-dose folic acid group. Figure 2 shows the median toxicity score for the three groups (0.685, 0.016, and 0.031 in the placebo, low-dose folic acid, and high-dose folic acid groups, respectively). The toxicity score for the placebo group was greater than those for the two folic acid–supplemented groups ($P = 0.001$ for both comparisons for low-dose folic acid and high-dose folic acid compared with placebo; $P = 0.71$ for low-dose folic acid compared with high-dose folic acid). The most frequently reported toxicities were nausea and indigestion (31 patients), diarrhea (11 patients), stomatitis (9 patients), and rash (9 patients). When the patients receiving hydroxychloroquine were omitted from the analyses, the results were identical.

Other Outcomes

Efficacy

As noted in Table 2, the percentages of patients who

Table 2. Joint Swelling and Tenderness at 6 and 12 Months in the Three Treatment Groups

Outcome	6 Months			12 Months		
	Placebo ($n = 23$)	Low-Dose Folic Acid ($n = 24$)	High-Dose Folic Acid ($n = 23$)	Placebo ($n = 19$)	Low-Dose Folic Acid ($n = 23$)	High-Dose Folic Acid ($n = 18$)
	←			%		→
Marked improvement						
Swelling	35	38	61	68	78	78
Tenderness	30	29	39	53	43	61
Moderate improvement						
Swelling	26	29	26	16	13	5
Tenderness	35	8	18	16	13	16
No change						
Swelling	35	33	9	11	5	17
Tenderness	26	55	39	21	35	17
Worsening						
Swelling	4	0	4	5	4	0
Tenderness	9	8	4	10	9	6

* $P > 0.5$ (chi-square) for comparisons among groups at 6 months and 12 months.

Table 3. Data for Efficacy and Other Outcomes at Baseline, 6 Months, and 12 Months*

Outcome	Placebo Group			Low-Dose Folic Acid Group			High-Dose Folic Acid Group		
	Baseline	6 Months	12 months	Baseline	6 Months	12 months	Baseline	6 Months	12 months
Joint indices for tenderness†	34 (2, 99)	21 (0, 61)	18 (4, 62)	32 (6, 112)	20 (2, 99)	21 (0, 90)	34 (2, 105)	26 (0, 66)	14 (2, 41)
Joint indices for swelling†	45 (6, 85)	25 (3, 51)	12 (0, 51)	51 (14, 85)	28 (2, 48)	14 (2, 40)	43 (18, 103)	20 (4, 62)	13 (1, 58)
Patient assessment of disease activity†	3 (2, 5)	2 (1, 4)	2 (2, 4)	3 (2, 5)	2 (1, 5)	2 (1, 5)	3 (2, 5)	2 (1, 4)	2 (1, 4)
Physician assessment of disease activity†	4 (2, 4)	3 (2, 4)	2 (2, 4)	4 (2, 5)	3 (2, 4)	2 (2, 3)	4 (2, 5)	3 (2, 5)	2 (2, 4)
Grip strength in right hand, mm Hg†	56.5 (5, 100)	66.7 (10, 205)	61.7 (9.3, 167)	40.5 (0, 173)	45 (13, 127)	48.3 (18.3, 133)	35 (5, 132)	53.3 (5, 180)	46.7 (8.3, 118)
Grip strength in left hand, mm Hg†	46.7 (4.3, 208)	56.7 (10, 223)	56.7 (10.7, 150)	40 (5, 243)	34.2 (5, 115)	48.3 (10, 152)	32.5 (1.3, 183)	30 (6.7, 190)	48.3 (10, 157)
Modified Health Assessment Questionnaire	1.8 (1, 3.4)		1.5 (1, 2.8)	2 (1, 3.8)		1.2 (1, 2.8)	2 (1.1, 3.4)		1.2 (1, 2.6)

* Median (minimum, maximum).

† $P < 0.05$ for time effects for the three treatment groups.

had marked improvement, moderate improvement, no improvement, or worsening were similar among the three groups ($P > 0.5$). We observed marked improvement in the pain and tenderness index after 12 months in 53%, 43%, and 61% of patients receiving placebo, low doses of folic acid, and high doses of folic acid, respectively. We found marked improvement in the swelling index in 68%, 78%, and 78% of patients receiving placebo, low doses of folic acid, and high doses of folic acid, respectively.

Patient Withdrawal and Dropout

We withdrew 13 patients because of noncompliance. One patient was withdrawn for taking additional folate supplements and one because diagnosis was reconsidered. Seven patients in the placebo group, 2 in the low-dose folic acid group, and 2 in the high-dose folic acid group discontinued methotrexate treatment because of toxic effects. More dropouts occurred in the placebo group (25%) than in the folic acid groups (8%) ($P = 0.08$).

Other Indices

As noted in Table 3, patient and physician assessment, joint indices for swelling and tenderness, and grip strength improved with time. We found significant time effects with respect to joint tenderness indices ($P = 0.025$), joint swelling indices ($P = 0.027$), physician assessment of disease ($P = 0.011$), patient assessment of disease ($P = 0.008$), right-hand grip strength ($P = 0.032$), and left-hand grip strength ($P = 0.047$). We observed no significant time–treatment interactions.

At the follow-up visits, changes in the median or mean values for the following variables were not statistically different among the groups: modified Health Assessment Questionnaire, erythrocyte sedimentation rate, hemoglobin level, hematocrit, leukocyte count, mean corpuscular volume, creatinine concentration, and aspartate aminotransferase or alkaline phosphatase levels. However, six of the patients in the placebo group had a mean corpuscular

volume of 100 fL or more at one or more follow-up visits compared with only one and none in the low-dose or high-dose folic acid groups, respectively ($P = 0.02$).

Mean baseline plasma folate levels were 15, 10, and 13.5 nmol/mL ($P > 0.1$), and mean baseline erythrocyte folate levels were 662, 591, and 624 nmol ($P > 0.1$) in the placebo, low-dose folic acid, and high-dose folic acid groups, respectively. After 1 year, mean plasma folate levels in the placebo group decreased to 4.8 nmol/mL ($P < 0.01$) and mean plasma folate levels increased four to five times from baseline values in the folic acid groups ($P < 0.001$). In contrast, mean erythrocyte folate levels in the low-dose and high-dose folic acid groups were little changed ($\pm 5\%$) from baseline values after 1 year, whereas levels in the placebo group decreased by approximately 50% (349 nmol/mL; $P < 0.001$ for baseline values compared with values at 1 year). Twelve (43%), 5 (20%), and 4 (15%) patients in the placebo, low-dose folic acid,


Figure 3. Toxicity score as a function of dietary folate intake in the placebo group. An exponential decay curve was fitted to the data. To convert micrograms to nanomoles, divide micrograms by 0.441 (the formula weight of folic acid is 441.4).

and high-dose folic acid groups, respectively, had erythrocyte folate levels less than 320 nmol/L (that is, <140 ng/mL) at one or more of the follow-up visits ($P = 0.02$).

Figure 3 shows the toxicity score in the placebo group plotted as a function of mean daily dietary folate intake. Negligible toxic effects occurred as the dietary folate intake was increased to more than 900 nmol/d (400 μg/d). We used a multivariate general linear model to evaluate the effects of the following factors on the toxicity score: sex, race, disease duration, previous folate-containing vitamin use, rheumatoid factor status, concurrent nonsteroidal anti-inflammatory drug use, concurrent prednisone use, previous disease-modifying antirheumatic drug use, dietary folate intake, and supplemental folate intake (placebo; 5 mg/wk; and 27.5 mg/wk). Because the toxicity score and dietary folate intake measurements were not normally distributed, we used their ranks in the analysis. The analysis indicated that dietary folate intake and supplemental folate intake were related to toxicity ($P = 0.016$ for dietary intake; $P = 0.016$ for supplemental folate intake). Dietary folate was negatively correlated with toxicity score, indicating that higher dietary folate intake reduced toxicity. With regard to supplemental folate intake, both the 5 mg and 27.5 mg/wk doses reduced toxicity compared with placebo, suggesting an ameliorative effect. No interaction occurred between the dietary and supplemental folate intakes ($P = 0.39$).

Discussion

This controlled trial shows that folic acid supplementation of 11 327 nmol (5 mg) or 62 302 nmol (27.5 mg) per week decreases methotrexate toxicity without compromising efficacy. The toxicity of methotrexate in both folic acid groups was low and nearly identical. The data suggest that dietary folate also helps protect against methotrexate toxicity. This finding suggests that the intake of one multiplevitamin pill containing 900 nmol of folic acid (400 μg/d) may also modulate methotrexate toxicity in patients with other micronutrient deficiencies (57).

We designed this trial using completers analysis. One year into the study, we considered modifying the trial toward intention-to-treat analysis. However, we could not have obtained complete data on the participants who had already withdrawn in the first year. We wanted to compare our study with other methotrexate clinical trials that used completers analyses and thus chose not to analyze the data by intent to treat. The overall results of the study were not greatly influenced by the study design. By using intent-to-treat analysis, we might have observed a lesser degree of difference for efficacy, but we would have observed the same toxic effects and resulting discontinuation of drug therapy.

We also re-examined the data on the basis of the most recent recommendations from the American College of Rheumatology for monitoring hepatic conditions in patients with rheumatoid arthritis who are receiving methotrexate, but this did not change the toxicity scores (58).

We previously showed that low baseline plasma and erythrocyte folate levels can predict future toxicity (29). Because large doses of folic acid can mask and exacerbate vitamin B_{12} deficiency, adequate vitamin B_{12} status should be assured before folic acid supplementation (59). Based on the data presented, baseline mean corpuscular volume, blood folate, and vitamin B_{12} values should be determined in patients in whom methotrexate will be initiated. Because anemia is a late finding in nutritional deficiencies, and patients may have dimorphic anemia (iron plus B_{12} or folate deficiency), yielding a normal mean corpuscular volume, we think vitamin levels are useful. There is no contraindication to starting folic acid at a dose of 5 to 7 mg/wk during methotrexate therapy initiation. Supplementation with higher doses may be indicated if an increasing mean corpuscular volume is observed or if suspected methotrexate toxic effects occur. The dose may be adjusted to levels as high as 27.5 mg/wk to control or reverse both of these clinical findings. Serial evaluation of the mean corpuscular volume has been suggested as an inexpensive means to monitor incipient toxicity (60). However, other investigators have found that the mean corpuscular volume does not predict toxicity in patients given folic acid (30). Our data suggest that a high mean corpuscular volume and a low blood folate level are often associated with methotrexate toxicity.

The mechanism or mechanisms by which folate produces the clinical effects on toxicity are not clear. Folinic acid, 5-formyl-tetrahydrofolic acid, also has been used to reduce side effects of methotrexate (31–36). Perhaps folic acid and folinic acid correct a state of folate deficiency, or perhaps folinic acid, by circumventing dihydrofolate reductase inhibition, relieves toxicity. However, these two mechanisms are not mutually exclusive.

The vitamin form and ratio of folate to methotrexate are important factors in determining whether efficacy will be lost with combination vitamin and antivitamin therapy. Because folinic acid is a fully reduced and one-carbon–substituted folate, it can bypass folate-metabolizing steps that reduce the pteridine moiety and add a one-carbon fragment. Table 4 shows the ratios of folate to methotrexate and clinical outcomes in previous studies. Folinic acid in relatively high doses negates the effectiveness of methotrexate therapy for rheumatoid arthritis (31). Our previous trial used a folic acid-to-methotrexate ratio of 0.93 to 1, causing decreased toxicity but not decreased efficacy (29). Similar results are now reported with a ratio as high as 2.85 to 1. The participants who received 27.5 mg/wk had a folate-to-methotrexate ratio that was much higher than in the folinic acid studies by Joyce and colleagues and Tishler and colleagues (31, 32), in which efficacy was negated. A study by Duhra (61) using 35 mg of folic acid per week during methotrexate therapy for psoriasis showed no loss of efficacy and supports a wide margin of safety for folic acid. Although folinic acid can lessen methotrexate toxicity, the dose level is more critical than that for folic acid.

The optimal dosing schedule of folate supplements in relation to methotrexate is not known. The half-life for oral, intramuscular, and intravenous low-dose methotrexate is about 4.5 to 13 hours (62–65). Table 4 shows the timing of the folate to methotrexate in previously published reports. In the studies by Joyce and associates (31), Tishler and coworkers (32), and Buckley and colleagues (34), folinic acid was given within the first half-life of the methotrexate dose. The ratio of folate to methotrexate used by these three investigators was 2.3, 0.95, and 0.5, respectively, with the lowest ratio causing no flare in

Table 4. Ratios of Folic Acid to Methotrexate and Folinic Acid to Methotrexate and Effects on Clinical Efficacy*

Reference	Weekly Folate-to-Methotrexate Ratio	Effect on Efficacy in Rheumatoid Arthritis	Timing of Folate Relative to Methotrexate Dose
Folinic acid†			
31	2.3 : 1	Flare in disease activity	Oral folinic acid 2 hours after weekly oral methotrexate dose
32	0.95 : 1	Flare in disease activity	15 mg oral folinic acid for 3 consecutive days, starting 4 to 6 hours after intravenous methotrexate dose
33	0.5 : 1	No adverse effect on disease activity	Folinic acid orally for 2 days, beginning 4 days before next intramuscular methotrexate dose
34	0.5 : 1	No adverse effect on disease activity	Oral folinic acid 4 hours after oral methotrexate dose
35	0.09 : 1	No change in efficacy—one patient in folinic acid arm for lack of efficacy	Oral folinic acid 24 hours after oral methotrexate dose
36	0.05 : 1	No change in efficacy	Oral folinic acid given simultaneously with oral methotrexate dose
Folic acid			
29	0.93 : 1	No change in efficacy	Not specified
30	1 : 1	No change in efficacy	Not specified
This trial	0.53 : 1 and 2.85 : 1	No change in efficacy	Folic acid administered on 2 days when oral methotrexate not taken

* Folic acid = Pteroylglutamic acid; folinic acid = 5-Formyl-tetrahydro-pteroylglutamic acid.
† Only one half of the folinic acid dose is biologically active because of the presence of stereoisomers.

disease activity. In contrast, when the two highest ratios were administered, a flare in disease activity occurred, which suggests that the ratio of folate to methotrexate, not the dosing interval, was more important in determining whether efficacy is altered.

The cost of folinic acid compared with that of folic acid therapy is also relevant (36). At our center, the price of a dose of folinic acid is 43 times greater than the price of an equivalent dose of folic acid; these figures are probably similar to costs nationwide. Thus, safety and cost would support folic acid as the better supplement. A controlled trial of folic acid and folinic acid would answer these questions most clearly.

The proposal to enrich flour with folic acid to prevent neural tube defects has led to concern about the possibility of negating the efficacy of methotrexate therapy in autoimmune diseases (66, 67). Neither our data nor the data of others support this concern (61). Enrichment of flour to provide folic acid intakes of 900 to 2265 nmol (400 μg to 1 mg/d) would not affect efficacy of low-dose methotrexate therapy for rheumatic disease.

The enzyme or enzymes that must be inhibited to allow for the efficacy of methotrexate therapy is not known. We have postulated that inhibition of aminoimidazole carboxamide ribotide transformylase is necessary for the efficacy of methotrexate therapy (68).

Widely varying dose levels of folic acid decrease the toxicity of methotrexate without affecting its efficacy. The flexibility in the dosing range, coupled with its low cost, make folic acid the preferred vitamin form to treat patients with rheumatoid arthritis who are taking methotrexate.

Appendix

Toxicity score = duration of toxic events [weeks] × (intensity) × (clinical severity factor) ÷ weeks in the protocol, where intensity is 1 (mild), 2 (moderate), or 3 (severe), as gauged by patient report; and the clinical

severity factor is 1 (alopecia, malaise or fatigue, nausea, pruritus, anorexia, or general gastrointestinal intolerance [pyrosis, cramps, and so on]), 2 (vomiting, diarrhea, stomatitis, rash, headache, elevated liver enzyme levels, peripheral nodulosis), 3 (elevated serum creatinine level), or 4 (cytopenias, documented infections, or pulmonary toxicity, systemic nodulosis, profound lethargy). Any abnormality in liver functions or complete blood cell count, documented infection, or pulmonary toxicity was given an intensity score of 3 (severe). Abnormal liver function tests were defined as an aspartate aminotransferase or an alkaline phosphatase level greater than two times baseline; cytopenias were defined as a leukocyte count less than 3.5 × 10^9/L or a platelet count less than 150 × 10^9/L; and serum creatinine concentration was considered elevated if more than 133 μmol/L (1.5 mg/dL). Pulmonary toxicity was defined as evidence of new interstitial pulmonary infiltrates from baseline chest radiograph and evidence of restrictive changes in pulmonary function tests, including vital capacity less than 80% of predicted value, normal expiratory flow rates, normal maximal voluntary ventilation, and carbon monoxide diffusion capacity less than 70% of normal. Infection was defined as a documented viral, bacterial, or fungal infection that compromised the patient greatly and required hospitalization or administration of systemic antimicrobial agents, or both.

Requests for Reprints: Sarah L. Morgan, MD, RD, 212 Webb, Department of Nutrition Sciences, U.A.B. Station, Birmingham, AL 35294-3360.

Current Author Addresses: Dr. Morgan: 212 Webb, Department of Nutrition Sciences, U.A.B. Station, Birmingham, AL 35294-3360.

Dr. Baggott: 340 Webb, Department of Nutrition Sciences, U.A.B. Station, Birmingham, AL 35294-3360.

Mr. Vaughan: 437 Webb, Department of Nutrition Sciences, U.A.B. Station, Birmingham, AL 35294-3360.

Ms. Austin: CH 19 420, U.A.B. Station, Birmingham, AL 35294-2041.

Ms. Veitch: 210 Webb, Department of Nutrition Sciences, U.A.B. Station, Birmingham, AL 35294-3360.

Dr. Lee: WTI 153, Cancer Center Biostatistics Unit, Division of Hematology/Oncology, Department of Medicine, U.A.B. Station, Birmingham, AL 35294-3300.

Dr. Koopman: 429A THT, Division of Clinical Immunology and Rheumatology, Department of Medicine, U.A.B. Station, Birmingham, AL 35294-0006.

Dr. Krumdieck: 326 Webb, Department of Nutrition Sciences, U.A.B. Station, Birmingham, AL 35294-3360.

Dr. Alarcón: 301 MEB, Division of Clinical Immunology and Rheumatology, Department of Medicine, U.A.B. Station, Birmingham, AL 35294-3296.

References

1. Hanno R, Gruber GG, Owen LG, Callen JP. Methotrexate in psoriasis. A brief review of indications, usage, and complications of methotrexate therapy. J Am Acad Dermatol. 1980;2:171-4.
2. Mullarkey MF, Blumenstein BA, Andrade WP, Bailey GA, Olason I, Wetzel CE. Methotrexate in the treatment of corticosteroid-dependent asthma. A double-blind crossover study. N Engl J Med. 1988;318:603-7.
3. Metzger AL, Bohan A, Goldberg LS, Bluestone R, Pearson CM. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med. 1974;81:182-9.
4. Owen ET, Cohen ML. Methotrexate in Reiter's disease. Ann Rheum Dis. 1979;38:48-50.
5. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 1992;35:1322-9.
6. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110:353-6.
7. Williams HJ, Willkens RF, Samuelson CO Jr, Alarcón GS, Guttadauria M, Yarbobo C, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1985;28:721-30.
8. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:818-22.
9. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med. 1985;103:489-96.
10. Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol. 1984;11:760-3.
11. Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum. 1992;35:129-37.
12. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 1991;35:138-45.
13. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol. 1989;16:313-20.
14. Alarcón GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 1989;32:671-6.
15. Gispen JG, Alarcón GS, Johnson JJ, Acton RT, Barger BO, Koopman WJ. Toxicity to methotrexate in rheumatoid arthritis. J Rheumatol. 1987;14:74-9.
16. Wolfe F, Cathey MA. The effect of age on methotrexate efficacy and toxicity. J Rheumatol. 1991;18:973-7.
17. Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J Rheumatol. 1990;17:1628-35.
18. Antonelli MA, Moreland LW, Brick JE. Herpes Zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med. 1991;90:295-8.
19. MacKinnon SK, Starkebaum G, Willkens RF. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 1985;15:119-26.
20. Cannon GW, Ward JR, Clegg DO, Samuelson CO Jr, Abbott TM. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum. 1983;26:1269-74.
21. Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax. 1992;47:628-33.
22. Walker AM, Funch D, Dreyer NA, Tolman KG, Kremer JM, Alarcón GS, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 1993;36:329-35.
23. Jackson RC. Biological effects of folic acid antagonists with antineoplastic activity. Pharmacol Ther. 1984;25:61-82.
24. Omer A, Mowat AG. Nature of anemia in rheumatoid arthritis. IX. Folate metabolism in patients with rheumatoid arthritis. Ann Rheum Dis. 1968;27:414-24.
25. Morgan SL, Baggott JE, Altz-Smith M. Folate status of rheumatoid arthritis patients receiving long term, low-dose methotrexate therapy. Arthritis Rheum. 1987;30:1348-56.
26. Hine RJ, Alarcón GS, Koopman WJ, Morgan SL, Baggott JE, Clegg DO, et al. Serum folate (FA) levels of rheumatoid arthritis (RA) patients treated with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs) [Abstract]. Arthritis Rheum. 1990;33:S60.
27. Wilke WS, Krall PL. Resistant rheumatoid arthritis. What to do when conservative therapy doesn't work. Postgrad Med. 1984;75:69-77.
28. Mackenzie AH. Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritis. Cleve Clin Q. 1985;52:129-35.
29. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33:9-18.
30. Stewart KA, Mackenzie AH, Clough JD, Wilke WS. Folate supplementation in methotrexate-treated rheumatoid arthritis patients. Semin Arthritis Rheum. 1991;20:332-8.
31. Joyce DA, Will RK, Hoffman DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis. 1991;50:913-4.
32. Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum. 1988;31:906-8.
33. Hanrahan PS, Russell AS. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol. 1988;15:1078-80.
34. Buckley LM, Vacek PM, Cooper SM. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1990;17:1158-61.
35. Shiroky JB, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993;36:795-803.
36. Weinblatt ME, Maier AL, Coblyn JS. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: An 8 week randomized placebo controlled trial. J Rheumatol. 1993;20:950-2.
37. Stenger AA, Houtman PM, Bruyn GA. Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate? Ann Rheum Dis. 1992;51:1019-20.
38. Morgan SL, Baggott JE, Koopman WJ, Krumdieck CL, Alarcón GS. Folate supplementation and methotrexate [Letter]. Ann Rheum Dis. 1993;52:315-6.
39. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
40. Pocock SJ, Simon R. Sequential treatment assignment with balancing of prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103-15.
41. Schakel SF, Sievert YA, Buzzard IM. Sources of data for developing and maintaining a nutrient database. J Am Diet Assoc. 1988;88:1268-71.
42. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Kummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346-53.
43. Tamura T. Microbiological assay of folates. In: Picciano MF, Stokstad EL, Gregory JF, eds. Folic Acid Metabolism in Health and Disease. New York: Wiley-Liss; 1990:121-37.
44. Horne DW, Patterson D. Lactobacillus casei microbiological assay of folic acid derivatives in 96-well microtiter plates. Clin Chem. 1988;34:2357-9.
45. Stacewicz-Sapuntzakis M, Bowen PE, Kikendall JW, Burgess M. Simultaneous determination of serum retinol and various carotenoids: their distribution in middle-aged men and women. Journal of Micronutrient Analysis. 1987;3:27-45.
46. Lau KS, Gottlieb C, Wasserman LR, Herbert V. Measurement of serum vitamin B_{12} level using radioisotope dilution and coated charcoal. Blood. 1965;26:202-14.
47. Omaye ST, Schaus EE, Kutnink MA, Hawkes WC. Measurement of

vitamin C in blood components by high-performance liquid chromatography. Implication in assessing vitamin C status. Ann N Y Acad Sci. 1987;498:398-401.

48. **Bayoumi RA, Rosalki SB.** Evaluation of methods of coenzyme activation of erythrocyte enzymes for detection of deficiency of vitamins B1, B2, and B6. Clin Chem. 1976;22:327-35.

49. **Waring PP, Fisher D, McDonnell J, McGown EL, Sauberlich HE.** A continuous-flow (AutoAnalyzer II) procedure for measuring erythrocyte transketolase activity. Clin Chem. 1982;28:2206-13.

50. **Skala JH, Gretz D, Waring PP.** An automated continuous-flow procedure for simultaneous measurement of erythrocyte alanine and aspartate aminotransferase activities. Nutrition Research. 1987;7:731-41.

51. **Baker H, Frank O.** Vitamin A and carotenes. In: Clinical Vitaminology. New York: Interscience Publishers; 1968.

52. **Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al.** How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. 1985;28:1326-35.

53. **Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, et al.** Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum. 1990;33:330-8.

54. **Cohen J.** Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press; 1977.

55. **Borenstein M, Cohen J.** Statistical Power Analysis: A Computer Program. Hilldale, New Jersey: Lawerence Erlbaum Associates; 1988.

56. **Subar AF, Block G, James LD.** Folate intake and food sources in the US population. Am J Clin Nutr. 1989;50:508-16.

57. **Morgan SL, Hine RJ, Vaughn WH, Brown A.** Dietary intake and circulating vitamin levels of rheumatoid arthritis patients treated with methotrexate. Arthritis Care Res. 1993;6:4-10.

58. **Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE,** Williams HJ, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;3:316-28.

59. **Butterworth CE Jr, Tamura T.** Folic acid safety and toxicity: a brief review. Am J Clin Nutr. 1989;50:353-8.

60. **Weinblatt ME, Fraser P.** Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum. 1989;32:1592-6.

61. **Duhra P.** Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol. 1993;28:466-9.

62. **Furst DE.** Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis. J Rheumatol. 1985;12:11-4.

63. **Sinnett MJ, Groff GD, Raddatz DA, Franck WA, Bertino JS Jr.** Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol. 1989;16:745-8.

64. **Edelman J, Biggs DF, Jamali F, Russell AS.** Low-dose methotrexate kinetics in arthritis. Clin Pharmacol Ther. 1984;35:382-6.

65. **Laffourgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquavia PC.** Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. J Rheumatol. 1993;20:263-7

66. **Centers for Disease Control and Prevention.** Recommendation for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep. 1992;41:1-7.

67. **Nightingale SL.** Proposals for folic acid fortification and labeling of certain foods to reduce risk of neural tube defects. JAMA. 1993;270:2283.

68. **Baggott JE, Morgan SL, Ha TS, Alarcón GS, Koopman WJ, Krumdieck CL.** Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol. 1993;11:S101-5.